Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.
Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Tamiya A, Nosaki K, Fukumitsu K, Akechi T. Hasegawa T, et al. Among authors: matsuda y. Oncologist. 2022 Nov 3;27(11):982-990. doi: 10.1093/oncolo/oyac178. Oncologist. 2022. PMID: 36067268 Free PMC article.
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.
Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Omachi N, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M. Nishie K, et al. Among authors: matsuda y. J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7. J Thorac Oncol. 2012. PMID: 23059777 Free article.
Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study.
Hamano J, Morita T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Yamamoto N, Shimizu M, Sasara T, Kinoshita H. Hamano J, et al. Among authors: matsuda y. Oncologist. 2015 Jul;20(7):839-44. doi: 10.1634/theoncologist.2015-0015. Epub 2015 Jun 8. Oncologist. 2015. PMID: 26054631 Free PMC article.
Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model.
Baba M, Maeda I, Morita T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Tei Y, Hiramoto S, Suga A, Kinoshita H. Baba M, et al. Among authors: matsuda y. Eur J Cancer. 2015 Aug;51(12):1618-29. doi: 10.1016/j.ejca.2015.04.025. Epub 2015 Jun 11. Eur J Cancer. 2015. PMID: 26074396
Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study.
Maeda I, Morita T, Yamaguchi T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Tei Y, Kikuchi A, Baba M, Kinoshita H. Maeda I, et al. Among authors: matsuda y. Lancet Oncol. 2016 Jan;17(1):115-22. doi: 10.1016/S1470-2045(15)00401-5. Epub 2015 Nov 29. Lancet Oncol. 2016. PMID: 26610854
Clinical Implications of C-Reactive Protein as a Prognostic Marker in Advanced Cancer Patients in Palliative Care Settings.
Amano K, Maeda I, Morita T, Miura T, Inoue S, Ikenaga M, Matsumoto Y, Baba M, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Nagaoka H, Mori M, Kinoshita H. Amano K, et al. Among authors: matsuda y. J Pain Symptom Manage. 2016 May;51(5):860-7. doi: 10.1016/j.jpainsymman.2015.11.025. Epub 2016 Jan 28. J Pain Symptom Manage. 2016. PMID: 26826676 Free article.
A prospective, multicenter cohort study to validate a simple performance status-based survival prediction system for oncologists.
Yamada T, Morita T, Maeda I, Inoue S, Ikenaga M, Matsumoto Y, Baba M, Sekine R, Yamaguchi T, Hirohashi T, Tajima T, Tatara R, Watanabe H, Otani H, Takigawa C, Matsuda Y, Ono S, Ozawa T, Yamamoto R, Shishido H, Yamamoto N. Yamada T, et al. Among authors: matsuda y. Cancer. 2017 Apr 15;123(8):1442-1452. doi: 10.1002/cncr.30484. Epub 2016 Dec 7. Cancer. 2017. PMID: 27926777 Free article.
Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients with Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase-R).
Okuyama T, Yoshiuchi K, Ogawa A, Iwase S, Yokomichi N, Sakashita A, Tagami K, Uemura K, Nakahara R, Akechi T; Phase‐R Delirium Study Group. Okuyama T, et al. Oncologist. 2019 Jul;24(7):e574-e582. doi: 10.1634/theoncologist.2018-0242. Epub 2019 Jan 4. Oncologist. 2019. PMID: 30610009 Free PMC article.
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M, Tamiya A, Suzuki H, Taniguchi Y, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Kumagai T, Atagi S, Imamura F, Hirashima T. Tamiya M, et al. Among authors: matsuda y. Invest New Drugs. 2021 Aug;39(4):1106-1112. doi: 10.1007/s10637-021-01076-8. Epub 2021 Feb 5. Invest New Drugs. 2021. PMID: 33544282 Clinical Trial.
3,902 results